Lung Cancer Medications

These drugs are being tested in clinical trials after surgery or chemoradiation in stage I to 3 lung cancer, but the evidence available so far do not demonstrate that they work in this setting. I do not recommend using these drugs in the curative-intent setting unless as part of a clinical trial. These drugs are being tested in clinical trials after surgery or chemoradiation in stage I to 3 lung cancer, but the evidence available so far do not demonstrate that they work in this setting. I do not recommend using these drugs in the curative-intent setting unless as part of a clinical trial.

Xalkori is very successful in causing tumor shrinkage in most patients whose tumors have an ALK fusion. Efficacy is usually measured by tumor shrinkage, time to progression or survival. Xalkori is very successful in causing tumor shrinkage in most patients whose tumors have an ALK fusion. Efficacy is usually measured by tumor shrinkage, time to progression or survival.

Cisplatin and alimta (pemetrexed) is a very reasonable adjuvant therapy, unless you had squamous type lung cancer. The choice of adjuvant therapy is an imprecise science, but the strongest evidence is for some regimen containing cisplatin, and avoiding pemetrexed in squamous cancer. Trials are underway to test the addition of bevacizumab to chemotherapy. Cisplatin and alimta (pemetrexed) is a very reasonable adjuvant therapy, unless you had squamous type lung cancer. The choice of adjuvant therapy is an imprecise science, but the strongest evidence is for some regimen containing cisplatin, and avoiding pemetrexed in squamous cancer. Trials are underway to test the addition of bevacizumab to chemotherapy.